<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529993</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-06</org_study_id>
    <nct_id>NCT04529993</nct_id>
  </id_info>
  <brief_title>An Atlas of Airways at a Single Cell Level in Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Controls</brief_title>
  <acronym>DISCOVAIR</acronym>
  <official_title>An Atlas of Airways at a Single Cell Level in Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing incidence of chronic respiratory disease is a public health problem that&#xD;
      affects hundreds of thousands of people worldwide at all ages. Directly exposed to&#xD;
      atmospheric airborne contaminants (pollution, allergens), the respiratory tract represents a&#xD;
      complex ecosystem involving different cells (multiciliated, basal, mucosecretory,&#xD;
      neuroendocrine, etc.) that develop complex interactions with the surrounding connective&#xD;
      tissue but also with their rich immune environment and the local microbiota. Although a&#xD;
      pathophysiological continuum is postulated between the nasal and bronchial airways in certain&#xD;
      diseases, such as allergic diseases, investigators have demonstrated large gene expression&#xD;
      gradients between samples taken from the nasal and bronchial airways in different studies.&#xD;
      Specifying the cellular variability throughout the respiratory tree in a normal physiological&#xD;
      situation is one of the major objectives defined in the establishment of an atlas of all&#xD;
      airway cells, as defined in the objectives of the international consortium Human Cell Atlas.&#xD;
&#xD;
      The sequencing of the RNAs present specifically in each individual cell (&quot;single-cell&#xD;
      RNAseq&quot;), and its comparison with neighbouring cells allows to document the precise cellular&#xD;
      contributions, as well as the signalling pathways involved. The development of tissue&#xD;
      sampling, stabilization, transport and single cell analysis procedures can be performed on&#xD;
      primary respiratory epithelium cultures and can also be extended to respiratory samples from&#xD;
      healthy volunteers.&#xD;
&#xD;
      This project will analyze gene expression profiles at the single cell level (single cell&#xD;
      RNAseq) in volunteers with chronic obstructive pulmonary disease, interstitial pulmonary&#xD;
      fibrosis and compared to healthy subjects of the same age. The technical modalities of the&#xD;
      samples will be brushing and staged airway biopsies for direct analysis of the samples. This&#xD;
      approach will be complemented by an air-liquid interface culture to allow secondary analysis&#xD;
      in single cell RNAseq and three-dimensional mapping of the distribution of these cells with&#xD;
      single cell in situ analysis.&#xD;
&#xD;
      Thanks to sampling at several levels of the respiratory tree (nose, bronchioles,&#xD;
      bronchioles), cellular and gene expression variations along the tracheobronchial axis will be&#xD;
      exhaustively documented in subjects of different ages, healthy or suffering from pathologies&#xD;
      such as chronic obstructive pulmonary disease and interstitial pulmonary fibrosis. These data&#xD;
      will serve as worldwide references for comparisons in different physiological and&#xD;
      pathological contexts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of samples usable</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Interstitial Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Interstitial pulmonary fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic obstructive pulmonary disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)</description>
    <arm_group_label>Chronic obstructive pulmonary disease</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Interstitial pulmonary fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Absence of acute pathology&#xD;
&#xD;
          -  Absence of symptom evoking an evolutionary pathology&#xD;
&#xD;
        For healthy volunteers :&#xD;
&#xD;
          -  Non-smoker (active or passive) or ex-smoker of less than 5 packet-years and quit for&#xD;
             more than 10 years.&#xD;
&#xD;
          -  Absence of known significant chronic pathology&#xD;
&#xD;
          -  Normal Respiratory Function Test (RFT)&#xD;
&#xD;
          -  Woman of childbearing age using an effective method of contraception&#xD;
&#xD;
        For COPD patients :&#xD;
&#xD;
          -  Diagnosis of COPD based on dyspnea, chronic cough or sputum production, a history of&#xD;
             recurrent lower respiratory tract infections and/or a history of exposure to risk&#xD;
             factors for the disease associated with spirometry that demonstrates a&#xD;
             post-bronchodilator FEV1/FVC ratio &lt; 0.70 and lack of reversibility.&#xD;
&#xD;
          -  Stage GOLD 1 (post-bronchodilator FEV1 â‰¥ 80% theoretical) or 2 (post-bronchodilator&#xD;
             FEV1 between 50 and less than 80% theoretical) or 3 (post-bronchodilator FEV1 between&#xD;
             30 and less than 50% theoretical) For IPF patients&#xD;
&#xD;
          -  Diagnosis of idiopathic pulmonary fibrosis made less than 5 years ago on the basis of&#xD;
             scannographic and/or histological criteria and validated at a consultation meeting on&#xD;
             interstitial pathology according to the ATS/ERS/JRS/ALAT 2018 recommendations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent rhino-bronchial infection (&lt; 6 weeks)&#xD;
&#xD;
          -  Subjects on antiplatelet or other anticoagulant medication at risk of bleeding during&#xD;
             sampling.&#xD;
&#xD;
          -  Subjects with a history of clinically significant vaginal discomfort (i.e., recurrent&#xD;
             or unconsciousness, etc.)&#xD;
&#xD;
          -  History of allergy or intolerance to xylocaine and/or propofol&#xD;
&#xD;
          -  History of significant epistaxis (i.e. recurrent epistaxis of any quantity or at least&#xD;
             one severe epistaxis)&#xD;
&#xD;
          -  Subject at risk of difficult intubation according to the criteria of the 2006 FSSR&#xD;
             expert conference*.&#xD;
&#xD;
          -  Pregnant (a urine test will be performed for all women of childbearing age) or&#xD;
             breastfeeding woman&#xD;
&#xD;
        For patients :&#xD;
&#xD;
          -  Long-term systemic corticosteroid therapy regardless of the reason for the&#xD;
             prescription.&#xD;
&#xD;
          -  Systemic corticosteroid therapy within the previous 3 months&#xD;
&#xD;
          -  Patient on long-term oxygen therapy&#xD;
&#xD;
          -  Chronic cardiovascular, neuro-psychic, metabolic pathology in progress, clinically&#xD;
             significant or uncontrolled in the last 6 months&#xD;
&#xD;
          -  Other associated chronic respiratory pathology (COPD, asbestosis, bronchiectasis ...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie LEROY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie LEROY, Dr</last_name>
    <email>leroy.s2@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvie LEROY, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Charles-Hugo MARQUETTE, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johana PRADELLI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>nasal mucosa</keyword>
  <keyword>respiratory mucosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

